Inventor
WIDDISON WAYNE C
US32 patents
⚠️ This page may combine multiple inventors who share the name “WIDDISON WAYNE C”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
IMMUNOGEN INC
25 patentsUS7368565B2May 6, 2008
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
IMMUNOGEN INC239 citations99
US7276497B2Oct 2, 2007
Cytotoxic agents comprising new maytansinoids
IMMUNOGEN INC402 citations99
US6441163B1Aug 27, 2002
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
IMMUNOGEN INC690 citations99
US7851432B2Dec 14, 2010
Cytotoxic agents comprising new maytansinoids
IMMUNOGEN INC54 citations98
US7473796B2Jan 6, 2009
Cytotoxic agents comprising new maytansinoids
IMMUNOGEN INC55 citations98
US7411063B2Aug 12, 2008
Process for preparation of maytansinol
IMMUNOGEN INC31 citations93
US7301019B2Nov 27, 2007
Method for the preparation of maytansinoid esters
IMMUNOGEN INC41 citations93
US9061995B2Jun 23, 2015
Cross-linkers and their uses
IMMUNOGEN INC17 citations92
US9498541B2Nov 22, 2016
Cross-linkers and their uses
IMMUNOGEN INC10 citations84
US7432088B2Oct 7, 2008
Methods for the production of ansamitocins
IMMUNOGEN INC15 citations83
US11135308B2Oct 5, 2021
Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
IMMUNOGEN INC1 citations73
US10792372B2Oct 6, 2020
Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
IMMUNOGEN INC2 citations73
US10494431B2Dec 3, 2019
Cross-linkers and their uses
IMMUNOGEN INC2 citations73
US10461449B2Oct 29, 2019
Methods for the acylation of maytansinol
IMMUNOGEN INC1 citations73
US9999680B2Jun 19, 2018
Conjugates comprising cell-binding agents and maytansinoids as cytotoxic agents
IMMUNOGEN INC4 citations73
US10944190B2Mar 9, 2021
Methods for the acylation of maytansinol
IMMUNOGEN INC0 citations63
US10100062B2Oct 16, 2018
Methods for the acylation of maytansinol
IMMUNOGEN INC1 citations63
US9796731B2Oct 24, 2017
Methods for the acylation of maytansinol
IMMUNOGEN INC1 citations63
US9469655B2Oct 18, 2016
Methods for the acylation of maytansinol
IMMUNOGEN INC2 citations63
US12390471B2Aug 19, 2025
Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
IMMUNOGEN INC0 citations62
US11046762B2Jun 29, 2021
Cross-linkers and their uses
IMMUNOGEN INC0 citations62
US11229639B2Jan 25, 2022
Camptothecin derivatives
IMMUNOGEN INC1 citations58
US10494423B2Dec 3, 2019
Maytansinoid derivatives with peptide linker and conjugates thereof
IMMUNOGEN INC0 citations52
US9901647B2Feb 27, 2018
Conjugates comprising cell-binding agents and cytotoxic agents
IMMUNOGEN INC0 citations52
US9518017B2Dec 13, 2016
Purification of intermediates used in the preparation of heterobifunctional linkers
IMMUNOGEN INC0 citations52
CHARI RAVI V J
4 patentsUS8685920B2Apr 1, 2014
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates
CHARI RAVI V J16 citations92
US8435528B2May 7, 2013
Cytotoxic agents comprising new maytansinoids
CHARI RAVI V J20 citations92
US8841425B2Sep 23, 2014
Cytotoxic agents comprising new maytansinoids
CHARI RAVI V J7 citations84
US9090629B2Jul 28, 2015
Cytotoxic agents comprising new ansamitocin derivatives
CHARI RAVI V J10 citations81